Experimental HCV Drugs
Experimental HCV Drugs
AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 22 April 2014 00:00
- Written by Keith Alcorn
A 3-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C virus (HCV) in a small Phase 2 study reported last week at the 49th EASL International Liver Congress (EASL 2014) in London.
EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 April 2014 00:00
- Written by Liz Highleyman
A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people with hepatitis C genotypes 1 through 6, according to Phase 2 results presented at the 49th EASL International Liver Congress last week in London.
EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% of Previously Untreated HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 16 April 2014 00:00
- Written by Keith Alcorn
A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, as well as all treatment-experienced patients followed for 4 weeks post-treatment, Christophe Hézode of Hôpital Henri Mondor in Paris reported at the 49th EASL International Liver Congress last week in London.
EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 April 2014 00:00
- Written by Liz Highleyman
A combination of 2 direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for genotype 1 hepatitis C patients, including people with cirrhosis or HIV/HCV coinfection, according to a series of presentations last week at the 49th EASL International Liver Congress in London.
EASL 2014: BMS Dual Combo Cures 90% of Genotype 1b Hepatitis C in 24 Weeks
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 16 April 2014 00:00
- Written by Keith Alcorn
A combination of 2 direct-acting antivirals developed by Bristol-Myers Squibb (BMS), daclatasvir and asunaprevir, cured 90% of previously untreated people with genotype 1b hepatitis C in 24 weeks, without the need for pegylated interferon or ribavirin, Michael Manns of Hannover Medical School reported at the 49thEASL International Liver Congress (EASL 2014) in London last week.
More Articles...
- EASL 2014: Sofosbuvir + Ribavirin Safe and Effective for Hepatitis C Patients with Advanced Liver Disease
- EASL 2014: AbbVie 3-drug Combination Cures Up to 96% of Hepatitis C Patients with Cirrhosis
- EASL 2014: Sofosbuvir + Simeprevir Shows High Cure Rates for Hep C Patients with or without Cirrhosis
- EASL 2014: Sofosbuvir + Ledipasvir Cures More than 90% of First-time and Retreated Genotype 1 Patients
Web Design and Development by